Have the potential to reduce organ fibrosis and protect against neuroinflammation. Clinically tested inhibitors show good safety but modest efficacy. More potent and specific inhibitors are in development.
Neuroprotective Benefit: Elevated galectin-3 is associated with cognitive decline. Galectin-3 inhibition may reduce pathological microglial neuroinflammation. Novel BBB penetrant inhibitors may need to be developed.
Aging and related health concerns: Elevated serum galectin-3 is a prognostic marker for reduced heart function, fibrotic disease, poor prognosis, and mortality. Inhibitors show potential benefits for fibrotic diseases in early clinical trials.
Safety: Good safety profile in clinical trials, but currently available inhibitors are relatively weak and non-specific. Many novel galectin-3 inhibitors are currently in preclinical development.
Written by
Bolt_Upright
To view profiles and participate in discussions please or .
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder worldwide. PD is characterized by progressive degeneration of the nigrostriatal dopaminergic pathway with substantial loss of substantia nigra pars compacta (SNpc) neurons and depletion of dopamine (DA) [116]. The pathologic characteristic of PD is the accumulation of α-synuclein, named Lewy bodies or Lewy neurites [117]. Clinical studies have shown that the serum Gal-3 level in idiopathic PD patients was higher than that in healthy controls, and it presented a significant correlation with Hoehn-Yahr scores, suggesting that Gal-3 is a biomarker for PD detection and the prediction of disease severity [118, 119]. A study noted that exogenous α-synuclein monomers or aggregates can activate microglia, induce upregulation of proinflammatory cytokines and participate in the neurodegenerative process of PD. When the expression of Gal-3 was inhibited by using siRNA or pharmacologically targeting Gal-3 activity, the α-synuclein-induced inflammatory response was alleviated. When α-synuclein was administered to wild-type mouse olfactory bulbs, activated microglia taking up α-synuclein developed a Gal-3-positive phenotype [94]."
I did not see a link, but I think this is it: Galectin-3: A New Target For Inflammation with Dr Isaac Eliaz 2020 youtu.be/P1wPE44eLwU
I found this newer article: Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration 2022 nature.com/articles/s41419-...
And found the product: PectaSol Powder econugenics.com/products/pe... $55 for 150 grams, dosage 15 grams a day = $165 a month. Maintenance dose is 5 grams a day, $55 a month.
I did not dig too deep, so everybody do their own research. The research does not seem anywhere close to the solution being sold. And it is really pricey. But you never know. I have a high school degree.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. (Wiley Online Library) 
Benfotiamine (Fat Soluble Form Of Vitamin B1) and AD
PharmaTher Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in PD
Promising disease modifying therapies for PD
